Literature DB >> 7047044

Renal handling of captopril: effect of probenecid.

S M Sinhvi, K L Duchin, D A Willard, D N McKinstry, B H Migdalof.   

Abstract

14C-Captopril was given intravenously to four normal subjects in a 4-mg priming dose followed by constant intravenous infusion of 1.7 mg/hr for 3.5 hr with and without concomitant probenecid. Steady-state levels of unchanged captopril were obtained between 1.5 and 3.5 hr. In the presence of probenecid, the average steady-state blood levels of total radioactivity were higher (36%) than on captopril alone. Unchanged captopril levels were slightly higher (14%) in the presence of probenecid. Kinetic evaluations were carried out exclusively on data for unchanged captopril. The average total body clearance (ClT) and renal clearance (ClR) of captopril in the absence of probenecid were 775 and 388 ml/kg/hr. The corresponding values for captopril with probenecid (631 and 217 ml/kg/hr) were lower. The average ratio of ClR to ClT for captopril alone was 0.50 and fell to 0.35 in the presence of probenecid. When captopril alone was given, a minimum of 78% of the renal excretion of captopril during steady-state could be attributed to net tubular secretion, but when captopril was given with probenecid, net tubular secretion was only 56%. The volume of distribution of captopril during steady state was not altered by probenecid. For the first 3.5 hr, cumulative renal excretion of total radioactivity with and without probenecid was 55% and 60%, but cumulative excretion of unchanged captopril was higher after captopril alone (36% of dose) than after the combination (21% of dose).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7047044     DOI: 10.1038/clpt.1982.145

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

Review 1.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

2.  Tubular transport mechanisms of quinapril and quinaprilat in the isolated perfused rat kidney: effect of organic anions and cations.

Authors:  A R Kugler; S C Olson; D E Smith
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

Review 3.  Potentially significant drug interactions of class III antiarrhythmic drugs.

Authors:  Weeranuj Yamreudeewong; Michael DeBisschop; Linda G Martin; Dennis L Lower
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

4.  Disposition of fosinopril sodium in healthy subjects.

Authors:  S M Singhvi; K L Duchin; R A Morrison; D A Willard; D W Everett; M Frantz
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

Review 5.  Fosinopril. Clinical pharmacokinetics and clinical potential.

Authors:  H Shionoiri; M Naruse; K Minamisawa; S Ueda; H Himeno; S Hiroto; I Takasaki
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

6.  Competitive inhibition of p-aminohippurate transport by quinapril in rabbit renal basolateral membrane vesicles.

Authors:  W Akarawut; D E Smith
Journal:  J Pharmacokinet Biopharm       Date:  1998-06

Review 7.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

8.  Reversible captopril-associated bone marrow aplasia.

Authors:  R K Strair; W E Mitch; D V Faller; K L Skorecki
Journal:  Can Med Assoc J       Date:  1985-02-15       Impact factor: 8.262

9.  Renal excretion of an angiotensin I converting enzyme inhibitor (SA-446) in dogs.

Authors:  Y Abe; T Okahara; K Miura; T Yukimura; T Takada; T Iwatani; T Iso; K Yamamoto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-04       Impact factor: 3.000

Review 10.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.